Giorgo Massimini
Chief Medical Officer CanWell Pharma Inc
Seminars
Wednesday 14th October 2026
Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist SMDC With First Line Potential in Liposarcoma
2:00 pm
- Introducing CAN1012 small molecule drug conjugate with TLR7 agonist immunomodulatory payload
- Laying out rationale for liposarcoma indication selection and CAN1012 early clinical data leading to Orphan Drug Designation
- Understanding the importance of indication selection in underserved cancer indications to maximize ADC first line potential and patient impact
